PEDIATRIC ONCOLOGY

该提案要求继续提供资金，以支持儿科 纽约州立大学(SUNY)肿瘤学项目。健康状况 锡拉丘兹科学中心，参与儿科 肿瘤学小组(POG)。儿科肿瘤学的机构项目是 一个跨学科的问题，涉及到辐射部门 肿瘤学、儿科外科、病理学、免疫学、神经外科和 神经科，以及儿科血液肿瘤科。 对锡拉丘兹方案的资助将使其能够继续 可评估的患者进入POG研究的出色记录。会的 也允许它的研究人员继续进行重要的科学研究 以及对POG的行政捐款。锡拉丘兹的教职员工 在制定和协调#8849号议定书方面的关键作用 (难治性白血病中的羟基脲-Arac)，#8823/24(α干扰素在 CML)和#8973(依托泊苷加卡铂持续输注 难治性白血病)。将从此启动的新协议 该机构将包括干扰素-化疗联合方案 用于慢性粒细胞白血病，以及利用TDT RNA检测的实验室研究 ALL患者缓解期骨髓标本，其中初步 发现，将价值升高的存在与随后的 复出，将进行前瞻性的测试。中国政府的积极参与 锡拉丘兹多个POG委员会的调查人员，特别是 数据管理员，将通过继续提供资金支持而成为可能。

This proposal requests continued funding to support the Pediatric Oncology program of the State University of New York (SUNY). Health Science Center at Syracuse, in its participation within the Pediatric Oncology Group (POG). The institutional program in Pediatric Oncology Is an interdisciplinary one, involving the Departments of Radiation Oncology, Pediatric Surgery, Pathology, Immunology, Neurosurgery, and Neurology, as well as the Division of Pediatric Hematology-Oncology. Funding of the Syracuse program will permit the continuation of its excellent record of evaluable patient entry onto POG studies. It will also allow the continuation of its investigators' significant scientific and administrative contributions to POG. Syracuse faculty have played key roles in developing and coordinating protocols #8849 (hydroxyurea-araC in refractory leukemia), #8823/24 (alpha interferon In CML), and #8973 (etoposide plus continuous infusion carboplatin in refractory leukemia). New protocols to be initiated from this institution will include a combination interferon-chemotherapy protocol for ACML, and a laboratory study utilizing an assay for TdT RNA in remission marrow specimens from patients with ALL, in which preliminary findings, relating the presence of elevated values to subsequent reslapse, will be tested prospectively. The active participation of Syracuse investigators on many POG committees, particularly that of the Data Manager, will be made possible by continuation of funded support.